1
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Antibodies against human CD40. Bristol Myers Squibb Co, Christopher A Klein, Audrey F Sher, April 18, 2000: US06051228 (81 worldwide citation)

The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent ant ...


2
Joseph A Hedrick, Frederick James Monsma Jr, Tatyana Churakova, Diane Hollenbaugh: Anti-PCSK9 and methods for treating lipid and cholesterol disorders. Merck Sharp & Dohme, Sheela Mohan Peterson, December 3, 2013: US08598320 (36 worldwide citation)

The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.


3
Alejandro Aruffo, Diane Hollenbaugh, Jeffrey A Ledbetter: Soluble and its use in B cell stimulation. Bristol Myers Squibb Company, Pennie & Edmonds, July 30, 1996: US05540926 (36 worldwide citation)

The present invention relates to soluble ligands for the B-cell antigen, CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell proliferation.


4
Elizabeth Bosch, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra: Compositions and methods of treating disease with FGFR fusion proteins. Five Prime Therapeutics, Finnegan Henderson Farabow Garrett & Dunner, March 16, 2010: US07678890 (28 worldwide citation)

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the ...


5
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath, William D Huse, Herren Wu, Jeffry D Watkins: Antibodies against human CD40. Joan E Switzer, November 6, 2001: US06312693 (21 worldwide citation)

The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transp ...


6
Elizabeth Bosch, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra: ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them. Five Prime Therapeutics, Finnegan Henderson Farabow Garrett & Dunner, May 8, 2012: US08173134 (16 worldwide citation)

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the ...


7
Lewis T Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang: FGFR3-IIIc fusion proteins. Five Prime Therapeutics, Finnegan Henderson Farabow Garrett & Dunner, July 19, 2011: US07982014 (14 worldwide citation)

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the ...


8
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Methods of using antibodies against human CD40. Bristol Myers Squibb Company, Joan E Switzer, July 2, 2002: US06413514 (11 worldwide citation)

A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection an ...


9
Lewis T Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang: Polynucleotides encoding FGFR1-IIIc ECD fusion proteins. Five Prime Therapeutics, Casimir Jones S C, November 12, 2013: US08580936 (9 worldwide citation)

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the ...


10
Alejandro Aruffo, Diane Hollenbaugh, Jeffrey A Ledbetter: Fusion proteins comprising gp39 and CD8. Bristol-Myers Squibb, Pennie & Edmonds, August 31, 1999: US05945513 (4 worldwide citation)

The present invention relates to fusion proteins having gp39 protein sequences, which fusion proteins bind to the B cell antigen, CD40. More specifically, the invention relates to fusion proteins having gp39 protein sequences attached to a polypeptide having an amino terminal secretory signal sequen ...